| Target Price | $36.72 | 
| Price | $9.30 | 
| Potential | 
      
            
    
      
    
  294.84%
     register free of charge | 
| Number of Estimates | 9 | 
| 9 Analysts have issued a price target Mersana Therapeutics, Inc. 2026 .
        The average Mersana Therapeutics, Inc. target price is $36.72.
        This is 
       
    
      
    
  294.84%
     register free of charge 
                $341.25 
    
      
    
  3,569.35%
     register free of charge 
                $8.08 
    
      
    
  13.12%
     register free of charge | |
| A rating was issued by 15 analysts: 13 Analysts recommend Mersana Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Mersana Therapeutics, Inc. stock has an average upside potential 2026 of 
       
    
      
    
  294.84%
     register free of charge | 
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Revenue Million $ | 40.50 | 25.80 | 
| 9.88% | 36.29% | |
| EBITDA Margin | -177.06% | -450.68% | 
| 61.48% | 154.53% | |
| Net Margin | -170.84% | -171.82% | 
| 63.32% | 0.57% | 
11 Analysts have issued a sales forecast Mersana Therapeutics, Inc. 2025 . The average Mersana Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Mersana Therapeutics, Inc. EBITDA forecast 2025. The average Mersana Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Mersana Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Mersana Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 | 2025 Estimates | |
|---|---|---|
| Earnings Per Share $ | -14.12 | -8.88 | 
| 61.80% | 37.11% | |
| P/E | negative | |
| EV/Sales | negative | 
10 Analysts have issued a Mersana Therapeutics, Inc. forecast for earnings per share. The average Mersana Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Mersana Therapeutics, Inc....
| Analyst | Rating | Action | Date | 
|---|---|---|---|
| Guggenheim | Locked ➜ Locked | Locked | Aug 14 2025 | 
| Truist Securities | Locked ➜ Locked | Locked | Aug 14 2025 | 
| Guggenheim | Locked ➜ Locked | Locked | May 16 2025 | 
| Truist Securities | Locked ➜ Locked | Locked | May 16 2025 | 
| William Blair | Locked ➜ Locked | Locked | Feb 06 2025 | 
| Citigroup | Locked ➜ Locked | Locked | Aug 27 2024 | 
| Analyst Rating | Date | 
|---|---|
| Locked 
            Guggenheim:
             Locked ➜ Locked | Aug 14 2025 | 
| Locked 
            Truist Securities:
             Locked ➜ Locked | Aug 14 2025 | 
| Locked 
            Guggenheim:
             Locked ➜ Locked | May 16 2025 | 
| Locked 
            Truist Securities:
             Locked ➜ Locked | May 16 2025 | 
| Locked 
            William Blair:
             Locked ➜ Locked | Feb 06 2025 | 
| Locked 
            Citigroup:
             Locked ➜ Locked | Aug 27 2024 | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


